AU2003232951B2 - Chimaeric human papillomavirus 16 L1 proteins comprising an L2 peptide, virus-like particles prepared therefrom and a method for preparing the particles. - Google Patents

Chimaeric human papillomavirus 16 L1 proteins comprising an L2 peptide, virus-like particles prepared therefrom and a method for preparing the particles. Download PDF

Info

Publication number
AU2003232951B2
AU2003232951B2 AU2003232951A AU2003232951A AU2003232951B2 AU 2003232951 B2 AU2003232951 B2 AU 2003232951B2 AU 2003232951 A AU2003232951 A AU 2003232951A AU 2003232951 A AU2003232951 A AU 2003232951A AU 2003232951 B2 AU2003232951 B2 AU 2003232951B2
Authority
AU
Australia
Prior art keywords
hpv
dna sequence
peptide
polypeptide
chimaeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003232951A
Other languages
English (en)
Other versions
AU2003232951A1 (en
Inventor
Edward Peter Rybicki
Arvind Devshi Varsani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Cape Town
Original Assignee
University of Cape Town
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29550639&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2003232951(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Cape Town filed Critical University of Cape Town
Publication of AU2003232951A1 publication Critical patent/AU2003232951A1/en
Application granted granted Critical
Publication of AU2003232951B2 publication Critical patent/AU2003232951B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003232951A 2002-05-17 2003-05-19 Chimaeric human papillomavirus 16 L1 proteins comprising an L2 peptide, virus-like particles prepared therefrom and a method for preparing the particles. Ceased AU2003232951B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ZA200203957 2002-05-17
ZA2002/3957 2002-05-17
PCT/IB2003/001912 WO2003097673A2 (en) 2002-05-17 2003-05-19 Chimeric human papillomavirus 16 l1 proteins comprising an l2 peptide,virus-like particles prepared therefrom and a method for preparing the particles.

Publications (2)

Publication Number Publication Date
AU2003232951A1 AU2003232951A1 (en) 2003-12-02
AU2003232951B2 true AU2003232951B2 (en) 2009-07-23

Family

ID=29550639

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003232951A Ceased AU2003232951B2 (en) 2002-05-17 2003-05-19 Chimaeric human papillomavirus 16 L1 proteins comprising an L2 peptide, virus-like particles prepared therefrom and a method for preparing the particles.

Country Status (13)

Country Link
US (2) US7407807B2 (enExample)
EP (1) EP1506222B2 (enExample)
JP (2) JP4614765B2 (enExample)
AT (1) ATE424409T1 (enExample)
AU (1) AU2003232951B2 (enExample)
CA (1) CA2486450C (enExample)
CY (1) CY1109257T1 (enExample)
DE (1) DE60326449D1 (enExample)
DK (1) DK1506222T3 (enExample)
ES (1) ES2323634T5 (enExample)
PT (1) PT1506222E (enExample)
SI (1) SI1506222T1 (enExample)
WO (1) WO2003097673A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228715D0 (en) * 2002-12-09 2003-01-15 Glaxosmithkline Biolog Sa Vaccine
CN101166827B (zh) 2005-04-29 2013-09-04 开普敦大学 在植物中表达蛋白质
ES2310062B1 (es) 2005-07-15 2009-11-13 Bionostra, S.L. Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
CN1328287C (zh) * 2005-12-29 2007-07-25 西安交通大学 Hpv16 l1蛋白模拟肽及其用于制备hpv16诊断试剂和疫苗的用途
US20100260792A1 (en) * 2007-10-22 2010-10-14 University Of Rochester Respiratory syncytial virus vaccine based on chimeric papillomavirus virus-like particles or capsomeres
CA2768172A1 (en) * 2009-06-25 2010-12-29 Glaxosmithkline Biologicals S.A. Novel compositions
WO2011017162A2 (en) * 2009-08-03 2011-02-10 The Johns Hopkins University Methods for enhancing antigen-specific immune responses
CA2799205A1 (en) 2010-05-25 2011-12-01 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically-truncated probes
CN103890177B (zh) * 2011-12-01 2016-03-09 开普敦大学 Hpv嵌合颗粒
WO2015009853A1 (en) * 2013-07-16 2015-01-22 University Of Louisville Research Foundation, Inc. Compositions for mucusal delivery, useful for treating papillomavirus infections
WO2015192018A1 (en) 2014-06-12 2015-12-17 Iowa Approach Inc. Method and apparatus for rapid and selective tissue ablation with cooling
JP7017811B2 (ja) * 2020-02-13 2022-02-09 国立研究開発法人農業・食品産業技術総合研究機構 ウイルス様粒子及びその使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
EP1728800A1 (de) * 1994-10-07 2006-12-06 Loyola University Of Chicago Papillomavirusähnliche Partikel, Fusionsproteine sowie Verfahren zu deren Herstellung
GB9621091D0 (en) * 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
US6228368B1 (en) † 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
DE19812941A1 (de) † 1998-03-24 1999-10-07 Medigene Ag Arzneimittel zur Vermeidung oder Behandlung von Papillomavirusspezifischem Tumor
US6926897B1 (en) † 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
DE69933875T2 (de) * 1998-08-14 2007-05-31 Merck & Co., Inc. Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt.
GB9921146D0 (en) † 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
EP2416798B1 (en) † 2009-04-10 2017-09-20 The Johns Hopkins University Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Jochmus, I. et al. (1999) Archives of Medical Research 30: 269-274 *
Muller, M. et al. (1997) Virology 234: 93-111 *
Slupetzky, K. et al. (2001) Journal of General Virology 82: 2799-2804 *

Also Published As

Publication number Publication date
US20060035319A1 (en) 2006-02-16
US8163557B2 (en) 2012-04-24
EP1506222B2 (en) 2012-05-23
CA2486450A1 (en) 2003-11-27
AU2003232951A1 (en) 2003-12-02
JP4614765B2 (ja) 2011-01-19
EP1506222B1 (en) 2009-03-04
US7407807B2 (en) 2008-08-05
PT1506222E (pt) 2009-06-12
ATE424409T1 (de) 2009-03-15
WO2003097673A2 (en) 2003-11-27
EP1506222A2 (en) 2005-02-16
DE60326449D1 (de) 2009-04-16
ES2323634T5 (es) 2012-09-04
WO2003097673B1 (en) 2004-04-22
WO2003097673A3 (en) 2004-03-18
CY1109257T1 (el) 2014-07-02
CA2486450C (en) 2013-11-19
SI1506222T1 (sl) 2009-10-31
US20090047302A1 (en) 2009-02-19
ES2323634T3 (es) 2009-07-22
DK1506222T3 (da) 2009-07-06
JP2010263899A (ja) 2010-11-25
JP2006507797A (ja) 2006-03-09

Similar Documents

Publication Publication Date Title
US8163557B2 (en) Chimaeric human papillomavirus 16 L1 virus-like particles and a method for preparing the particles
Suzich et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.
JP5296665B2 (ja) ヒトパピローマウイルスカプソメアワクチン製剤の製造方法
ES2213754T3 (es) Particulas quimericas de tipo papilomavirus.
Fligge et al. Induction of type-specific neutralizing antibodies by capsomeres of human papillomavirus type 33
EP1305039B1 (en) Stable (fixed) forms of viral l1 capsid proteins, fusion proteins and uses thereof
US6352696B1 (en) Papillomavirus truncated L1 protein and fusion protein constructs
US6649167B2 (en) Papillomavirus truncated L1 protein and fusion protein constructs
US7182947B2 (en) Papillomavirus truncated L1 protein and fusion protein constructs
CN114127127B (zh) 嵌合的人乳头瘤病毒35型l1蛋白
CN114127095B (zh) 嵌合的人乳头瘤病毒11型l1蛋白
CN114127096B (zh) 嵌合的人乳头瘤病毒31型l1蛋白
Sapp et al. Synthesis, properties and applications of papillomavirus-like particles
US7494658B2 (en) Papilloma virus truncated L1 protein and fusion protein constructs
Deng et al. The preparation of human papillomavirus type 58 vaccine and exploring its biological activity and immunogenicity in vitro
Kazaks et al. 11 Papillomavirus-Derived Virus-Like Particles
MXPA00003358A (en) Papilloma virus capsomere vaccine formulations and methods of use
Becker et al. Chimeric Human Papillomavirus Type 16
HK1094340A (en) Papilloma virus capsomere vaccine formulations and methods of use

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired